|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00389857 |
To provide CBER with sera collected from healthy children receiving the 2006-2007 formulation of the inactivated, split-virion influenza vaccine Fluzone® for further study by FDA, CDC and WHO.
Condition | Intervention | Phase |
Influenza Vaccines |
Biological: Influenza Virus Vaccine |
Phase IV |
MedlinePlus related topics: | Flu |
ChemIDplus related topics: | Influenza Vaccines Fluvirin |
Study Type: | Interventional |
Study Design: | Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 6 Months to 36 Months |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Related Info 
  |
Related Info 
  |
Responsible Party: | Sanofi Pasteur, Inc. ( Medical Monitor ) |
Study ID Numbers: | GRC34 |
First Received: | October 18, 2006 |
Last Updated: | January 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00389857 |
Health Authority: | United States: Food and Drug Administration |
|
|
|